Sun.Dec 24, 2023

article thumbnail

Slideshow: 2023 Vaccine Approvals

Drug Topics

Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.

Vaccines 196
article thumbnail

Top 5 Pharmacy Student Articles of 2023

Pharmacy Times

From newsworthy moments to groundbreaking research, these were the most-read student-related articles on Pharmacy Times in 2023.

65
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

2023 In Review for The Digital Apothecary

The Digital Apothecary

So, 2023 is coming to a close, and 2024 is upon us soon. With that being the case, I thought I'd summarize what I have been up to and what I look forward to next year! 2023 Areas of Focus This year, my focus was largely on AI and digital health technologies (DHTs). My anticipation of the societal impact of AI, which I expressed last December, has proven accurate.

PTCE 52
article thumbnail

2024 BCACP Exam Information

Med Ed 101

The (Ambulatory Care Pharmacist) BCACP exam is changing in 2024. Pharmacists should expect a shorter exam. BPS announced that the exam will drop from 175 questions to 150 questions. When the BCACP credential was initially created, the exam was 200 questions. The 2024 BCACP content outline has remained consistent from 2023 so in general I […] The post 2024 BCACP Exam Information appeared first on Med Ed 101.

52
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Lenvatinib mesylate by Eisai for Metastatic Biliary Tract Cancer: Likelihood of Approval

Pharmaceutical Technology

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer.

40